A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
Recruiting now · Phase 1
Conditions studied: Surgical Wound Infection, Traumatic Wound Infection
In brief
The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are: 1. Is Amicidin-β topical solution safe to test in larger clinical trials? 2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application? 3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
Key facts
- Study ID
- NCT07379684
- Run by
- Macro Biologics, Inc.
- People needed
- 44
- Starts
- 2026-08-31
- Expected to finish
- 2027-02-28
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lundquist Institute — Torrance, California, United States (enrolling)
- Snake River Research, PLLC — Idaho Falls, Idaho, United States (enrolling)
- LifeBridge Health — Baltimore, Maryland, United States (enrolling)
- Washington University in St. Louis — St Louis, Missouri, United States (enrolling)
- The Ohio State University — Columbus, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.